{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:52:48Z","timestamp":1791103968803,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11864-011-0176-y","type":"journal-article","created":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T10:53:56Z","timestamp":1326797636000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["Current Treatment Options for Metastatic Head and Neck Cancer"],"prefix":"10.1007","volume":"13","author":[{"given":"Katharine A. R.","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra E.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"issue":"19","key":"176_CR1","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1056\/NEJMoa065497","volume":"356","author":"G D\u2019Souza","year":"2007","unstructured":"D\u2019Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944.","journal-title":"N Engl J Med"},{"issue":"9420","key":"176_CR2","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0140-6736(04)16194-1","volume":"363","author":"ML Gillison","year":"2004","unstructured":"Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet. 2004;363(9420):1488.","journal-title":"Lancet"},{"issue":"7","key":"176_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cncr.22963","volume":"110","author":"EM Sturgis","year":"2007","unstructured":"Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110(7):1429\u201335.","journal-title":"Cancer"},{"issue":"4","key":"176_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. CA: Clin Lung Canc. 2011;61(4):212\u201336.","journal-title":"CA: Clin Lung Canc"},{"key":"176_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1368-8375(02)00163-X","volume":"39","author":"M Gasco","year":"2003","unstructured":"Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol. 2003;39:222\u201331.","journal-title":"Oral Oncol"},{"key":"176_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/hed.1046","volume":"23","author":"M Smit","year":"2001","unstructured":"Smit M, Balm A, Hilgers F, et al. Pain as sign of recurrent disease in head and neck squamous cell carcinoma. Head & Neck. 2001;23:372\u20135.","journal-title":"Head & Neck"},{"key":"176_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jnci\/djn011","volume":"100","author":"C Fakhry","year":"2008","unstructured":"Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"176_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival in patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335.","journal-title":"N Engl J Med"},{"issue":"suppl 8","key":"176_CR9","first-page":"viii314","volume":"21","author":"S Urba","year":"2010","unstructured":"Urba S, van Herpen CM, Sahoo TP, et al. Phase III study of pemetrexed in combination with cisplatin (pem\/cis) versus placebo plus cisplatin (cis) in patients with recurrent or metastatic squamous cell head and neck cancer (HNC). Ann Oncol. 2010;21 suppl 8:viii314.","journal-title":"Ann Oncol"},{"key":"176_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/BF00263902","volume":"15","author":"RP Morton","year":"1985","unstructured":"Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial. Canc Chemother Pharmacol. 1985;15:283\u20139.","journal-title":"Canc Chemother Pharmacol"},{"key":"176_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bjc.1990.59","volume":"61","author":"The Liverpool Head and Neck Oncology Group","year":"1990","unstructured":"The Liverpool Head and Neck Oncology Group. A phase III randomized trial of cisplatinum, methotrexate, cisplatinum\u2009+\u2009methotrexate and cisplatinum\u2009+\u20095-FU in end stage squamous cell carcinoma of the head and neck. Br J Cancer. 1990;61:311\u20135.","journal-title":"Br J Cancer"},{"key":"176_CR12","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/1097-0142(19840501)53:9<1819::AID-CNCR2820530903>3.0.CO;2-R","volume":"53","author":"MS Kish","year":"1984","unstructured":"Kish MS, Weaver A, Jacobs J, et al. Cisplatinum and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer. 1984;53:1819.","journal-title":"Cancer"},{"issue":"2","key":"176_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","volume":"10","author":"C Jacobs","year":"1992","unstructured":"Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257\u201363.","journal-title":"J Clin Oncol"},{"issue":"8","key":"176_CR14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","volume":"10","author":"AA Forastiere","year":"1992","unstructured":"Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245\u201351.","journal-title":"J Clin Oncol"},{"key":"176_CR15","first-page":"681","volume":"9","author":"MG Fury","year":"2011","unstructured":"Fury MG, Pfister DG. Current recommendations for systemic therapy of recurrent and\/or metastatic head and neck squamous cell cancer. JNCCN. 2011;9:681\u201390.","journal-title":"JNCCN"},{"key":"176_CR16","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","volume":"23","author":"MK Gibson","year":"2005","unstructured":"Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an Intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562\u20137.","journal-title":"J Clin Oncol"},{"key":"176_CR17","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q","volume":"82","author":"AA Forastiere","year":"1998","unstructured":"Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck. Cancer. 1998;82:2270\u20134.","journal-title":"Cancer"},{"issue":"3 suppl 6","key":"176_CR18","first-page":"41","volume":"22","author":"RE Smith","year":"1995","unstructured":"Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol. 1995;22(3 suppl 6):41\u20136.","journal-title":"Semin Oncol"},{"key":"176_CR19","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1996.14.5.1672","volume":"14","author":"AI Dreyfuss","year":"1996","unstructured":"Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"176_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.bjc.6690715","volume":"81","author":"C Couteau","year":"1999","unstructured":"Couteau C, Chouaki N, Leyvraz S, et al. A phase II study of docetaxel in patients with squamous cell carcinoma of the head and neck. Br J Cancer. 1999;81(3):457\u201362.","journal-title":"Br J Cancer"},{"issue":"6","key":"176_CR21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/oxfordjournals.annonc.a058908","volume":"5","author":"G Catimel","year":"1994","unstructured":"Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994;5(6):533\u20137.","journal-title":"Ann Oncol"},{"key":"176_CR22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a058910","volume":"5","author":"G Catimel","year":"1994","unstructured":"Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994;5:543\u20137.","journal-title":"Ann Oncol"},{"key":"176_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/A:1010657609609","volume":"19","author":"WE Samlowski","year":"2001","unstructured":"Samlowski WE, Gundacker H, Kuebler JP, et al. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study. Invest New Drugs. 2001;19:311\u20135.","journal-title":"Invest New Drugs"},{"issue":"2","key":"176_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/00000421-199804000-00021","volume":"21","author":"A Sandler","year":"1998","unstructured":"Sandler A, Saxman S, Bandealy M, et al. Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial. Am J Clin Oncol. 1998;21(2):195\u20137.","journal-title":"Am J Clin Oncol"},{"key":"176_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000226902","volume":"4892","author":"JC Cervellino","year":"1991","unstructured":"Cervellino JC, Araujo CE, Pirisi C, et al. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study. Oncology. 1991;4892:89\u201392.","journal-title":"Oncology"},{"issue":"4","key":"176_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00000421-199608000-00012","volume":"19","author":"M Huber","year":"1996","unstructured":"Huber M, Lippman S, Benner S, et al. A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am Journal Clin Oncol. 1996;19(4):379\u201383.","journal-title":"Am Journal Clin Oncol"},{"issue":"4","key":"176_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/BF00685683","volume":"31","author":"M Martin","year":"1993","unstructured":"Martin M, Diaz-Rubio E, Gonzalez Larriba JL, et al. Ifosfamide in advanced epidermoid head and neck cancer. Canc Chemother Pharmacol. 1993;31(4):340\u20132.","journal-title":"Canc Chemother Pharmacol"},{"key":"176_CR28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1023\/A:1008446706578","volume":"9","author":"M Degardin","year":"1998","unstructured":"Degardin M, Oliveira J, Geoffrois J, et al. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 1998;9:1103\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"176_CR29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00000421-199808000-00016","volume":"21","author":"S Saxman","year":"1998","unstructured":"Saxman S, Mann B, Canfield V, et al. A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol. 1998;21(4):398\u2013400.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"176_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF00873964","volume":"12","author":"A Testolin","year":"1994","unstructured":"Testolin A, Recher G, Cristoferi V, et al. Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study. Investig New Drugs. 1994;12(3):231\u20134.","journal-title":"Investig New Drugs"},{"key":"176_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1054\/bjoc.2001.2010","volume":"85","author":"X Pivot","year":"2001","unstructured":"Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001;85:649\u201355.","journal-title":"Br J Cancer"},{"key":"176_CR32","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/sj.bjc.6605697","volume":"102","author":"J Martinez-Trufero","year":"2010","unstructured":"Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer. 2010;102:1687\u201391.","journal-title":"Br J Cancer"},{"issue":"1","key":"176_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/14656566.6.1.85","volume":"6","author":"BA Murphy","year":"2005","unstructured":"Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother. 2005;6(1):85\u201392.","journal-title":"Expert Opin Pharmacother"},{"key":"176_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/annonc\/mdm591","volume":"19","author":"BA Burtness","year":"2008","unstructured":"Burtness BA, Manola J, Axelrod R, et al. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5\u00a0days every 3\u00a0weeks or weekly in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group study. Annals Oncol. 2008;19:977\u201383.","journal-title":"Annals Oncol"},{"key":"176_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.2004.08.039","volume":"22","author":"A Argiris","year":"2004","unstructured":"Argiris A, Li Y, Murphy BA, et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol. 2004;22:262\u20138.","journal-title":"J Clin Oncol"},{"key":"176_CR36","first-page":"7350","volume":"62","author":"KK Ang","year":"2002","unstructured":"Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350\u20136.","journal-title":"Cancer Res"},{"key":"176_CR37","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose. N Engl J Med. 2008;358:1109\u201317.","journal-title":"N Engl J Med"},{"key":"176_CR38","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116\u201327.","journal-title":"N Engl J Med"},{"key":"176_CR39","doi-asserted-by":"publisher","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol. 2005;23:8646\u201354.","journal-title":"J Clin Oncol"},{"key":"176_CR40","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171\u20137.","journal-title":"J Clin Oncol"},{"key":"176_CR41","unstructured":"Vermorken JB, Stohlmacher J, Davidenko I, et al: Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients (pts) with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (pmab). ESMO 2010.This abstract reports clinical activity but no survival benefit with the addition of panitumumab to chemotherapy in patients with R\/M HNSCC."},{"key":"176_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(11)70034-1","volume":"12","author":"J Machiels","year":"2011","unstructured":"Machiels J, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomized phase 3 trial. Lancet Oncol. 2011;12:333\u201343.","journal-title":"Lancet Oncol"},{"key":"176_CR43","doi-asserted-by":"crossref","unstructured":"Hitt R, Irigoyen A, Cortes-Funes H, et al: Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck. Annals Oncology 2011, August 23, epub ahead of print.","DOI":"10.1093\/annonc\/mdr367"},{"key":"176_CR44","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.2003.10.051","volume":"21","author":"EE Cohen","year":"2003","unstructured":"Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD 1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980\u20137.","journal-title":"J Clin Oncol"},{"key":"176_CR45","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2008.17.0530","volume":"27","author":"JWS Stewart","year":"2009","unstructured":"Stewart JWS, Cohen EEW, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1864\u201371.","journal-title":"J Clin Oncol"},{"key":"176_CR46","doi-asserted-by":"publisher","first-page":"15s","DOI":"10.1200\/JCO.2008.21.7695","volume":"27","author":"A Argiris","year":"2009","unstructured":"Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol. 2009;27:15s. suppl; abstr 6011.","journal-title":"J Clin Oncol"},{"key":"176_CR47","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1200\/JCO.2010.33.3591","volume":"29","author":"A Argiris","year":"2011","unstructured":"Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140\u20135.","journal-title":"J Clin Oncol"},{"key":"176_CR48","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1158\/0008-5472.CAN-08-2881","volume":"69","author":"TY Seiwert","year":"2009","unstructured":"Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69:3021\u201331.","journal-title":"Cancer Res"},{"key":"176_CR49","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-08-3252","volume":"15","author":"LM Knowles","year":"2009","unstructured":"Knowles LM, Stabile LP, Egloff AM, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 2009;15:3740\u201350.","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"176_CR50","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1200\/jco.2010.28.15_suppl.5500","volume":"28","author":"S Schmitz","year":"2010","unstructured":"Schmitz S, Kaminsky-Forrett M, Henry S, et al. Phase II study of figitumumab in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02. J Clin Oncol. 2010;28(suppl):5500.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0176-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-011-0176-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0176-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0176-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:38:18Z","timestamp":1659091098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-011-0176-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,18]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["176"],"URL":"https:\/\/doi.org\/10.1007\/s11864-011-0176-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,18]]},"assertion":[{"value":"18 January 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}